By highlighting the association of LIV1 expression with clinical outcome and potential sensitivity, vulnerability, or actionability to drugs currently used or developed in BC, our results may provide novel insights into the clinical development and use of LIV1-targeted ADC. This evidence concerns the gene SLC39A6 and breast cancer.